MetaCap

ALX Oncology (ALXO) vs ProQR Therapeutics N.V. (PRQR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ALX Oncology (ALXO) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, losing 25.9% versus a loss of 49.5%. Over five years, PRQR leads with a -85.5% price change compared with -96.8% for ALXO. ProQR Therapeutics N.V. is the larger company by market cap ($147.0 million vs $137.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALXO-25.87%PRQR-49.51%
+88%+16%-56%
Nov 21, 20251 yearNov 20, 2026
ALXO-97.23%PRQR-86.62%
+11%-47%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALXO versus PRQR key metrics
MetricALXOPRQR
Share price$1.06$1.04
Market cap$137.03M$146.98M
1-day change+3.92%-0.95%
YTD return-6.19%-48.51%
1-year return-25.87%-49.51%
5-year return-96.84%-85.54%
EPS (TTM)$-0.87$-0.43
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-101.69M—
52-week high$2.66$2.49
52-week low$0.862$1.00
Distance from 52-week high-60.15%-58.15%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+333.96%+626.92%
Average volume1.19M793.64K
Shares outstanding129.27M141.33M
Employees49186
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ALXO has outperformed PRQR by 23.6 percentage points over the past year.

About ALX Oncology

ALXO stock →

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About ProQR Therapeutics N.V.

PRQR stock →

ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.

Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees

ALXO vs PRQR FAQ

Which is bigger, ALX Oncology or ProQR Therapeutics N.V.?

ProQR Therapeutics N.V. (PRQR) is larger, with a market capitalization of $146.98M compared with $137.03M for ALX Oncology (ALXO).

Which stock has performed better over the past year, ALXO or PRQR?

ALXO returned -25.87% over the past 12 months, compared with -49.51% for PRQR (price return, excluding dividends). Past performance does not predict future results.

Are ALX Oncology and ProQR Therapeutics N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons